Oxford Biomedica (OXB)
Quick facts
| Ticker | OXB (LSE) |
|---|
Phase 3 pipeline
- Standard of care therapy · Oncology
This drug is a standard of care therapy.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: